Heparan sulfate glycosaminoglycans (HS-GAGs) are not only the structural elements of tissue architecture but also regulate the bioavailability and transduction pathways of heparan sulfate-bound polypeptides released by cells or the extracellular matrix. Heparan sulfate-bound polypeptides include inflammatory mediators, chemokines, angiogenic factors, morphogens, and growth-promoting factors that induce cell migration, proliferation, and differentiation in wound healing. OTR4120, a polymer engineered to mimic the properties of HS-GAGs, is used to replace the natural HS-GAGs that are degraded during wound repair, and enhance the tissue regeneration by preserving the cellular microenvironment and the endogenous signals needed for tissue regeneration. We previously demonstrated that OTR4120 treatment had a long-term effect on increasing breaking strength and vasodilation in healing rat full-thickness excisional wounds. The present study investigates the underlying mechanisms of the effects of OTR4120 treatment in improving the quality of cutaneous wound repair. We found that OTR4120 treatment stimulated inflammation resolution and increased neovascularization. OTR4120 treatment also promoted epidermal migration and proliferation during reepithelialization. Moreover, the granulation tissue formation and collagen maturation were improved in OTR4120-treated wounds. Three months after wounding, the effects of OTR4120 treatment on vascularization and inflammation resolution were normalized, except for an improved neodermis. We conclude that OTR4120 is a potential matrix therapeutic agent that ensures the quality of normal cutaneous wound repair and may restore impaired wound healing characterized by deficient angiogenesis and prolonged inflammation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1524-475X.2009.00548.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA in Dogs.
Vet Sci
December 2019
Organ, Tissue, Regeneration, Repair and Replacement Company (OTR3), F-75001 Paris, France.
Superficial corneal ulcers that fail to heal within a normal time period and are refractory to conventional therapy in dogs are common in veterinary practice. Different etiologies can lead to this result, including spontaneous chronic corneal epithelial defects (SCCEDs) and ulcerative keratitis associated with bullous keratopathy. Thus, there is an urgent need to find new therapeutic approaches such as matrix therapy replacement.
View Article and Find Full Text PDFMatrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies.
Regen Med Res
December 2019
OTR3, SAS, 4 rue Française, 75001 Paris, France - CRRET (EA 4397/ERL CNRS 9215), Université Paris-Est, Créteil 94010, France.
Article Synopsis
- Chronic, non-healing ulcers are serious medical issues that often lead to amputations and significant healthcare costs; the RGTA device CACIPLIQ20 (OTR4120) was evaluated for effectiveness in treating these ulcers in patients with advanced peripheral arterial disease.
- A pilot study involving 12 patients showed that OTR4120, applied twice a week, led to a 35% reduction in ulcer size after 4 weeks, with 50% of ulcers completely healed in 1 to 3 months.
- The results suggest that OTR4120 is a promising and cost-effective treatment option that can substantially improve the quality of life for patients with chronic lower extremity ulcers.
Treatment of spontaneous corneal perforation secondary to undiagnosed Sjögren's syndrome using regenerating agent and autologous serum eye drops.
Eur J Ophthalmol
January 2021
2nd Department of Ophthalmology, Faculty of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.
Purpose: The aim of this study was to report a case of sterile corneal ulcer leading to perforation, which was treated effectively with autologous serum eye drops, topical regenerative agent (poly-carboxymethylglucose sulfate), steroids, and systemic immunosuppression in a patient with undiagnosed primary Sjögren's syndrome.
Methods: A 74-year-old female presented with a month's history of gradually worsening blurry vision in her left eye. Ophthalmic examination revealed a central descemetocele with excessive corneal stromal melting and absence of signs of infection.
Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent.
J Fr Ophtalmol
February 2019
Service d'Ophtalmologie, hôpital Morvan, CHU de Brest, 2, avenue Foch, 29609 Brest, France.
Purpose: To assess the success rate of a matrix regenerating agent (RGTA) in the treatment of chronic corneal ulcers resistant to conventional treatments.
Methods: Uncontrolled prospective observational study in patients with corneal neurotrophic ulcer (Stage 2 or 3 of the Mackie classification), unresponsive to standard medical or surgical treatments and managed with RGTA as an adjunctive treatment. Corneal ulcers were evaluated using slit-lamp examination and optical coherence tomography after 2 weeks, 1 month, 2 months and 3 months.
Evaluation of corneal epithelial wound healing after penetrating keratoplasty in patients receiving a new matrix therapy agent (regenerating agent).
Eur J Ophthalmol
January 2020
Department of Ophthalmology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Objectives: Complete epithelial wound healing is a milestone in early postoperative care after penetrating keratoplasty. The re-epithelialization rate after penetrating keratoplasty was measured in patients receiving a new matrix therapy agent (regenerating agent, Cacicol) that mimics heparan sulphates.
Methods: This was a prospective, open-label, uncontrolled, single-centre observational study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!